About Careers Internship MedBlog Contact us

Tata Group Pharma Firm Tie-up With Geneva-based DNDi for the Research of Kala-azar

by Medindia Content Team on October 12, 2007 at 4:13 PM
Tata Group Pharma Firm Tie-up With Geneva-based DNDi for the Research of Kala-azar

The Advinus Therapeutics (P) Ltd, a Tata Group pharmaceutical company based in Bangalore, has begun a partnership with the Geneva-based Drugs for Neglected Diseases initiative (DNDi) for discovery and development of therapies for visceral leishmaniasis, commonly known in India as Kala-azar.

Kala-azar is a fatal and infectious disease, which occurs in the developing world, including India and Africa. The collaboration is the first of its kind in India to find a therapy for the neglected disease.


Current treatments have significant drawbacks, either in terms of route of administration, length of treatment (21-28 days) or emerging parasitic resistance.

The collaboration, which will be for five years for now, brings together expertise in chemistry, biology, screening, and pre-formulation, and will help to strengthen capacity in Kala-azar endemic countries through training and networking.

The goal of the project is to find molecules proven to be safe and active against leishmania parasites in early stage and to screen research through the first steps of regulatory safety assessment in the pre-clinical phase, Advinus Therapeutics said in a release here Thursday.

"India today is one of the few countries in the world that not only has the disease burden, but also the capability and capacity to research and develop new therapies for these diseases," Rashmii Barbhaiya, CEO and MD of Advinus, said.

Bernard Pecoul of DNDi said the project should serve as a model for future drug development for neglected diseases.

The Drugs for Neglected Diseases initiative is a not-for-profit drug development initiative established in 2003 by five publicly funded research organisations - Malaysia's Ministry of Health, Kenya Medical Research Institute, Indian Council of Medical Research, Oswaldo Cruz Foundation Brazil, and the Institut Pasteur.

It is also supported by Médecins Sans Frontières and WHO's special programme for research and training in tropical diseases and is working on 18 healthcare research projects worldwide.

Source: IANS
Font : A-A+



Recommended Readings

Latest Research News

Brain Circuits That Shape Bedtime Rituals in Mice
New study sheds light on the intrinsic, yet often overlooked, role of sleep preparation as a hardwired survival strategy.
NELL-1 Protein Aids to Reduce Bone Loss in Astronauts
Microgravity-induced bone loss in space, can be reduced by systemic delivery of NELL-1, a protein required for bone growth and its maintenance.
Connecting Genetic Variants to the Alzheimer's Puzzle
Researchers establish connections between Alzheimer's-linked genetic alterations and the functioning of brain cells.
Gene Therapy Sparks Spinal Cord Regeneration
Team at NeuroRestore introduces a groundbreaking gene therapy that has effectively promoted nerve regrowth and reconnection, post spinal cord injury.
Unlocking the Gut Microbiome's Influence on Bone Density
Scientists aim to pinpoint particular functional pathways affected by these bacteria that may have an impact on skeletal health.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
Greetings! How can I assist you?MediBot

Tata Group Pharma Firm Tie-up With Geneva-based DNDi for the Research of Kala-azar Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests